Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.

Z M van der Spuy, Zephne M. van der Spuy, M.J.A. Wood, M Wood, Graham Fieggen, G Fieggen, M S Hendricks
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde · 1993 · vol. 83(7) , pp. 510–3 · PMID:8211493 · W2410544201
article OA: green CC0 ⤵ 2 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Serum CA 125 fell during GnRH agonist treatment in endometriosis patients, reflecting therapeutic progress and potentially obviating surgical follow-up, but did not correlate with uterine fibroid shrinkage.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We assessed the possible role of CA 125 in the monitoring of gonadotrophin-releasing hormone (GnRH) agonist analogue therapy in women with endometriosis and uterine fibroids. Serum concentrations of this cell surface antigen did not correlate with uterine volume and appeared to have no value in the assessment of shrinkage of uterine fibroids during GnRH agonist treatment. While CA 125 levels were not always elevated in subjects with endometriosis, they fell during treatment in all patients. The change accurately reflected therapeutic progress in these women and was of particular value in those patients who had commenced therapy with elevated levels. It is suggested that CA 125 may be useful in the monitoring of therapeutic progress in selected patients with endometriosis treated with GnRH agonists; the need for surgical follow-up may be obviated.
Full text 1,521 characters · extracted from oa-html · 2 sections · click to expand

Abstract

We assessed the possible role of CA 125 in the monitoring of gonadotrophin-releasing hormone (GnRH) agonist analogue therapy in women with endometriosis and uterine fibroids. Serum concentrations of this cell surface antigen did not correlate with uterine volume and appeared to have no value in the assessment of shrinkage of uterine fibroids during GnRH agonist treatment. While CA 125 levels were not always elevated in subjects with endometriosis, they fell during treatment in all patients. The change accurately reflected therapeutic progress in these women and was of particular value in those patients who had commenced therapy with elevated levels. It is suggested that CA 125 may be useful in the monitoring of therapeutic progress in selected patients with endometriosis treated with GnRH agonists; the need for surgical follow-up may be obviated. Description

Keywords

Reference: van der Spuy, Z.M., Wood, M., Fieggen, G. & Hendricks, M. 1993. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues. South African Medical Journal. 83(7):510 - 513. http://hdl.handle.net/11427/34841

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Antigens, Tumor-Associated, Carbohydrate Endometriosis Gonadotropin-Releasing Hormone Leiomyoma Uterine Neoplasms Antigens, Tumor-Associated, Carbohydrate Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Leiomyoma Leiomyoma Uterine Neoplasms Uterine Neoplasms

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:11:39.448046+00:00
License: CC0 · commercial use OK